Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: Impact of bioavailability on costs and outcomes

PharmacoEconomics

Volumn 22, Issue 10, 2004, Pages 671-683

  Mittmann, Nicole ^a,b   Oh, Paul I ^a,b   Walker, Scott E ^b,c   Bartle, William R ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ARTICLE; BIOAVAILABILITY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; ECONOMIC ASPECT; GOVERNMENT; HEALTH; HEALTH CARE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MORBIDITY; PHYSICIAN; PRIORITY JOURNAL; PROBABILITY; RISK; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; HEALTH CARE COSTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MARKOV CHAINS; MODELS, ECONOMIC; THROMBOEMBOLISM; WARFARIN;

EID: 3242724774     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422100-00005     Document Type: Article

References (21)

1. Hirsh J, Dalen J, Deykin D, et al. Oral anticoagulants: mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (4 Suppl.): 231S-46S
2. Hirsh J, Dalen J, Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis: American College of Chest Physicians. Chest 2001; 119 (1 Suppl.): 1S-2S
3. White R, Zhou H, Romano P, et al. Changes in plasma warfarin levels and variations in steady state prothrombin times. Clin Pharmacol Ther 1995; 58 (5): 588-93
4. Basskin L. A pharmacoeconomic analysis of Coumadin versus generic warfarin. Formulary 1998; 33: 573-87
5. Benson SR, Vance-Bryan K. In favor of coumadin over generic warfarin. Am J Health Syst Pharm 1998; 55: 727-9
6. Rodger M, Bredeson C, Wells P, et al. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in the treatment of deep vein thrombosis. CMAJ 1998; 159 (8): 931-8
7. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10
8. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-39
9. Laupacis A, Feeny D, Detsky A, et al. How attractive does a technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473-81
10. Laupacis A, Feeny D, Detsky A, et al. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ 1993; 148 (6): 927-9
11. Richton-Hewett S, Foster E, Apstein C. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988; 148: 806-8
12. Food and Drug Administration. FDA position on product selection for "narrow therapeutic index" drugs. Am J Health Syst Pharm 1997; 54: 1630-2
13. Milligan P, Banet G, Waterman A, et al. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002; 36: 764-8
14. Neutel JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep 1998; 19 (2): 49-59
15. Handler J, Nguyen TT, Rush S, et al. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prev Cardiol 1998; 4: 13-20
16. DeCara J, Croze S, Falk R. Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card? Chest 1998; 113 (2): 261-2
17. Friesen M, Walker S. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated bioequivalence model. J Pharm Pharm Sci 1999; 2 (1): 15-22
18. Petersen P, Boyson G, Godtfedsen J, et al. Placebo-controlled randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; I: 175-9
19. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687-91
20. Hellemons B, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised control trial comparing two intensities of coumarin with aspirin. BMJ 1999; 319: 958-64
21. Gullov AL, Koefoed BG, Petersen P, et al. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation. Arc Intern Med 1999; 159 (12): 1322-8